Irritability in children with RASopathies, insights into emotional dysregulation and social impairment.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
RASopathies, including Noonan Syndrome (NS) and Neurofibromatosis type 1 (NF1), are developmental disorders caused by germline mutations in genes of the RAS-mitogen-activated protein kinase pathway (RAS-MAPK). This study investigates irritability, a highly prevalent transdiagnostic construct, in children with NS and NF1 and the impact of RASopathy status on the associations between irritability, emotional dysregulation-related disorders, and social impairment. The sample comprises 174 children aged 4–17 (age mean = 9.49; 98 females), including 113 children with RASopathies (NS n = 85, NF1 n = 28) and 61 age-sex-matched typically developed (TD) children. We used parent proxy questionnaires (CBCL, SRS) to assess irritability, symptoms of ADHD, defiance, anxiety/depression, and social impairment while controlling for cognitive measures (IQ). Children with RASopathies exhibited higher irritability than TD children (mean difference = 1.09; p <.001). Children with NS showed a weaker association between irritability and ADHD symptoms compared to TD children (p =.032, ηp2 = 0.03) and a stronger association between irritability and social impairment compared to both TD (p =.033, ηp2 = 0.03) and NF1 groups (p =.009, ηp2 = 0.06). We present novel and clinically significant findings showing high irritability in children with NS and NF1. Our study provides syndrome-specific results, suggesting differences in the mechanisms involved in irritability, ADHD, and social processes. In essence, children with RASopathies showed a highly irritable profile associated with ADHD symptoms and social impairment, with a significantly stronger association between irritability and social processes in NS. Our results suggest that developing prevention and treatments targeting irritability can distinctly affect the trajectories of neurodevelopmental disorders in children with NS and NF1.